ReviewJournal of the National Cancer Center2026
Transcriptional and epigenetic reprogramming, lineage plasticity and therapy resistance in prostate cancer.
Review in Journal of the National Cancer Center, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- The pseudouridine epitranscriptomic landscape of advanced prostate cancer therapeutic resistance identifies TIMM17A as a key player.Translational oncology · 2026Article
- Targeting the Androgen Receptor and Associated Cofactors in Prostate Cancer: Novel Approaches and Future Perspectives.International journal of molecular sciences · 2026Review
- Article
- Advances in Mechanism of Action and Efficacy of CBP/p300 Inhibitors in Different Subtypes of Breast Cancer.Molecules (Basel, Switzerland) · 2026Review
- Decoding the archipelago: single-cell biomarkers rechart the molecular geography of acute myeloid leukemia.Cell communication and signaling : CCS · 2026Review
- Decoding prostate cancer therapy resistance and novel therapeutic strategies.Journal of the National Cancer Center · 2026Article
- Review
- Endocrine-driven inflammatory-epigenetic adaptation as a proposed axis of radioresistance in endocrine-exposed prostate cancer: a translational hypothesis.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is the most commonly diagnosed and the second-leading cause of cancer-related mortality in men worldwide, especially in Western counties. Therapeutic resistance of prostate cancer remains a major challenge in modern oncology, necessitating new scientific understanding of the disease and devising new targeting strategies. This review examines the intricate relationship between transcriptional and epigenetic reprogramming, lineage plasticity, and therapeutic resistance in prostate cancer. Prostate cancer cells can adapt and resist various treatment modalities, including androgen deprivation therapy (ADT) and next-generation androgen receptor (AR) signaling inhibitors (ARSI), through transcriptional reprogramming and epigenetic modifications. Lineage plasticity, the ability of cells to alter their cellular identities, further drives treatment resistance. Moreover, cancer cells can adjust their gene expression profiles to evade therapy by activating key transcription factors and epigenetic regulatory mechanisms such as DNA methylation, histone modification, and non-coding RNA expression. The article concludes by discussing new therapeutic strategies targeting these reprogramming and plasticity mechanisms, emphasizing the importance of combination therapy and precision medicine in developing more effective treatments for advanced prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.